Bayer launches inovative hypertension products
Bayer has launched an innovate hypertension drug under the trade name Kinzalmono (telmisartan). The active substance will also be available together with a diuretic in a combination product called Kinzalkomb.
Bayer has launched an innovate hypertension drug under the trade name Kinzalmono (telmisartan). The active substance will also be available together with a diuretic in a combination product called Kinzalkomb.
Telmisartan is an angiotensin II receptor blocker, and clinical trials have shown that once daily administration ensures a powerful blood pressure-lowering effect over a 24-hour period.
In late 2002, Bayer signed a licensing agreement with Boehringer Ingelheim to market Kinzalmono and Kinzalkomb. Telmisartan and the combination product containing telmisartan and a diuretic were developed by Boehringer Ingelheim. Bayer will market the product initially in Germany, with further launches in the Netherlands, Switzerland, Denmark, Sweden and Finland to follow in the coming weeks. The products will be launched in Norway and Belgium in the autumn of 2003.
Dr Christa Kreuzburg, head of Europe in Bayer HealthCare's pharmaceuticals division, said: 'Kinzalmono and Kinzalkomb are excellent additions to our comprehensive range of cardiovascular risk management products.'